- $680.63m
- $658.47m
Brief: Nuvectis Pharma Announces Orphan Drug Tag Granted By FDA For The Treatment Of Cholangiocarcinoma
Nuvectis Pharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Nuvectis Pharma, Inc. Q2 EPS USD -0.38
Nuvectis Pharma Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Nuvectis Pharma Inc Says As Of June 30 Co Has About $24.5 Mln Of Cash And Cash Equivalents
Brief: Nuvectis Pharma Set To Join The Russell 2000 And Russell 3000 Indexes
Brief: Nuvectis Pharma Announces FDA Clearance Of NXP900 IND
Brief: Nuvectis Pharma Announces FDA Clearance Of NXP900 IND
Brief: Nuvectis Pharma Inc Reports First Quarter 2023 Financial Results
Brief: Nuvectis Pharma Initiates Phase 1B Study For Ovarian Cancer Drug
Brief: Nuvectis Pharma Initiate Phase 1B Study For Nxp800 In A Type Of Ovarian Cancer
Brief: Nuvectis Pharma Inc Files For Mixed Shelf Of Up To $150 Million - SEC Filing
Brief: Nuvectis Pharma Inc Reports Fiscal Year 2022 Financial Results And Business Highlights
Brief: Nuvectis Pharma With ENGOT, GOG Foundation To Conduct NXP800 Phase 1b Clinical Trial
U.S. STOCKS ON THE MOVE-Silver miners, PVH Corp, energy firms
Nuvectis Pharma rises on FDA's 'fast track' tag for ovarian cancer therapy
Brief: FDA Grants Fast Track Designation To Nuvectis Pharma's Nxp800 For The Treatment Of Platinum-Resistant, Arid1a-Mutated Ovarian Carcinoma
Brief: Nuvectis Pharma Reports Third Quarter Results
Brief: Nuvectis Pharma Announces Preclinical Data For NXP800